| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| ARK Investment Management · Cathie Wood | $37.2M | 0.24% | 1.37M | New | Q2 2026 |
| Soros Fund Management · George Soros | $1.6M | 0.02% | 60.00K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ALMR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Ragusa Robert P.Director | Stock Award(Grant) at price 0.00 per share. | 5.7K | — |
| Apr 19, 2026 | Naclerio Nicholas J.Director | Stock Award(Grant) at price 0.00 per share. | 5.7K | — |
| Apr 19, 2026 | Naclerio Nicholas J.Director | Purchase at price 22.00 per share. | 235.3K | $5.18M |
| Apr 19, 2026 | Naclerio Nicholas J.Director | — | 617.8K | — |
| Apr 19, 2026 | Mcanear Justin JChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 37.2K | — |
| Apr 19, 2026 | Illumina Innovation Fund Ii Gp, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 22.00 per share. | 235.3K | $5.18M |
| Apr 19, 2026 | Illumina Innovation Fund Ii Gp, L.L.C.Beneficial Owner of more than 10% of a Class of Security | — | 617.8K | — |
| Apr 19, 2026 | Luo Yuling Ph.D.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 76.5K | — |
| Apr 19, 2026 | Chen Shiping Ph.D.Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 37.2K | — |
| Apr 19, 2026 | White TimothyPresident | Stock Award(Grant) at price 0.00 per share. | 37.2K | — |
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
Buy / hold / sell counts